Menu Search
Equities

Talkmed Group Ltd

5G3:SES

Talkmed Group Ltd

Actions
Health CareHealth Care Providers
  • Price (SGD)0.41
  • Today's Change0.00 / 0.00%
  • Shares traded51.60k
  • 1 Year change0.00%
  • Beta0.3093
Data delayed at least 10 minutes, as of Jul 26 2024 07:11 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TalkMed Group Limited is a Singapore-based investment holding company. The Company provides medical oncology and palliative care healthcare services. Its segments include Oncology services, and Cellular and gene therapy related products and services. Oncology services segment comprises medical oncology services targeting various cancers, such as breast cancer, colon cancer, lung cancer, liver, biliary and pancreatic cancers, gastro-intestinal cancers, head and neck cancers, leukemia, hematology malignancies and brain cancer. It includes Parkway Cancer Centre, Thu Cuc International General Hospital. The Cellular and gene therapy related products and services segment includes provision of goods and services related to cellular and gene therapy through its subsidiaries, CellVec Pte. Ltd., and BioCell Innovations Pte. Ltd. The Company, through the Parkway Cancer Centre (PCC)-vehicle, offers a support system to cater to the psychosocial needs of its patients and their families.

  • Revenue in SGD (TTM)79.12m
  • Net income in SGD27.71m
  • Incorporated2013
  • Employees53.00
  • Location
    Talkmed Group Ltd101 Thomson Road, #09-02 United Square 307591SingaporeSGP
  • Phone+65 62586918
  • Fax+65 62580648
  • Websitehttps://www.talkmed.com.sg/
More ▼

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Invesense Asset Management Ltd.as of 30 Jun 20246.20k0.00%
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.